Hepatitis B Vaccine
Journal: Annals of Internal Medicine (1984)

Position Papers1 January 1984Hepatitis B VaccineHEALTH AND PUBLIC POLICY COMMITTEEHEALTH AND PUBLIC POLICY COMMITTEESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-100-1-149 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA safe, highly effective, licensed vaccine for the prevention of hepatitis B virus infection is available. Hepatitis B is a common and serious disease with an annual incidence in the United States of 200 000 cases. Seventy-five percent of patients with hepatitis B have mild or subclinical disease, 25% develop jaundice, 5% require hospitalization, and 0.1% die of fulminant disease; 6% to 10% of infected patients become chronic carriers. Of the 600 000 to 800 000 carriers in the United States, approximately 25% develop chronic hepatitis and approximately 4000 die of cirrhosis each year. In addition, 1% to 2% of...References1. Inactivated Hepatitis B virus vaccine. MMWR. 1982;31:317-28. MedlineGoogle Scholar2. Hepatitis B virus safety: report of an inter-agency group. MMWR. 1982;31:465-7. MedlineGoogle Scholar3. SZMUNESSSTEVENSHARLEY WCE. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833-41. CrossrefMedlineGoogle Scholar4. SZMUNESSSTEVENSZANGHARLEYKELLNER WCEEA. A controlled clinical trial of the efficacy of the hepatitis B vaccine: a final report. Hepatology. 1981;1:377-85. CrossrefMedlineGoogle Scholar5. FRANCISHADLERTHOMPSON DSS. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982;97:362-6. LinkGoogle Scholar6. KRUGMAN S. The newly licensed hepatitis B vaccine. JAMA. 1982;247:2012-5. CrossrefMedlineGoogle Scholar7. CROSNIERJUNGERSCOUROUCÉ JPA. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: 1, medical staff. Lancet. 1981;1:455-9. CrossrefMedlineGoogle Scholar8. MAUPASCHIRONBARIN PJF. Efficacy of hepatitis B vaccine in prevention of early HBsAG carrier state in children: controlled trial in an endemic area (Senegal). Lancet. 1981;1:289-92. CrossrefMedlineGoogle Scholar9. DIENSTAGSTEVENSBHANSZMUNESS JCAW. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann Intern Med. 1982;96:575-9. LinkGoogle Scholar10. PATTISONMAYNARDBERQUISTWEBSTER CJKH. Epidemiology of hepatitis B in hospital personnel. Am J Epidemiol. 1975;101:59-64. CrossrefMedlineGoogle Scholar11. DIENSTAGRYAN JD. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization. Am J Epidemiol. 1982;115:26-39. CrossrefMedlineGoogle Scholar12. FRANCISFAVEROMAYNARD DMJ. Transmission of hepatitis B virus. Semin Liver Dis. 1981;1:27-32. CrossrefMedlineGoogle Scholar13. MULLEYSILVERSTEINDIENSTAG AMJ. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med. 1982;307:644-52. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: AMERICAN COLLEGE OF PHYSICIANS Philadelphia, Pennsylvania*This paper was authored by J. Sanford Schwartz, M.D., and developed for the Health and Public Policy Committee by the Clinical Efficacy Assessment Subcommittee: Donald E. Olson, M.D., Chairman; David Banta, M. D.; Alvan R. Feinstein, M.D.; Howard S. Frazier, M.D.; Richard B. Hornick, M.D.; and Seymour Perry, M.D. Members of the Health and Public Policy Committee for the 1983-1984 term were Edwin P. Maynard, III, M.D., Chairman; Arthur J. Atkinson, Jr., M.D.; Steven C. Beering, M.D.; Richard G. Farmer, M.D.; Paul F. Griner, M.D.; John R. Hogness, M.D.; Charles E. Lewis, M.D.; Donald E. Olson, M.D.; Malcolm L. Peterson, M.D.; Theodore B. Schwartz, M.D.; and Helen L. Smits, M.D. Richard J. Reitemeier, M.D., and Francis J. Sweeney, Jr., M.D., were ex officio members. This position paper was adopted by the Executive Committee of the Board of Regents on 28 September 1983. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDiagnosis and treatment of von Willebrand diseaseHepatitis B in the non-residential mentally handicapped populationCost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.Inflammatory nodular reactions after hepatitis B vaccination due to aluminium sensitizationAdult ImmunizationAn Assessment of Clinically Useful Measures of the Consequences of TreatmentVaccines and antibody immunotherapy in surgical patientsThe prevalence of serological markers for hepatitis B virus infection amongst anaesthetists in the Oxford regionImpaired Immunogenicity of Hepatitis B Vaccine in Obese PersonsImmunizing the adultCase reportsThe Clinical Efficacy Assessment Project of the American Collegeof PhysiciansHepatitis B vaccines 1 January 1984Volume 100, Issue 1Page: 149-150KeywordsCirrhosisHepatitis BHospitalizationsInfectious diseasesInfectious hepatitisPrevention, policy, and public healthPublic policySafetySub-specialty careVaccines ePublished: 1 December 2008 Issue Published: 1 January 1984 Copyright & Permissions© 1984 American College of PhysiciansPDF downloadLoading ...